What Is VIP Peptide?
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide belonging to the VIP/glucagon/secretin peptide family. It primarily binds the VPAC1 and VPAC2 class B G protein-coupled receptors.
VIP is a peptide signaling molecule produced from the prepro-VIP precursor. Its amino-acid sequence is conserved between human and porcine VIP, and published studies have characterized its molecular structure, receptor binding and receptor interactions.
Research Overview Table
Chemical and Molecular Characteristics
VIP is a 28-amino-acid, C-terminally amidated neuropeptide. Its sequence contains both charged and hydrophobic residues, with structural studies showing helical character within the peptide, particularly toward the C-terminal region.
VIP belongs to the VIP/PACAP peptide family and shares sequence features with related secretin-family peptides. Its defined amino-acid sequence and C-terminal amide distinguish it from non-amidated peptide forms and shorter VIP fragments.
Certificates:
Mechanism of Action Under Investigation
VIP binds the VPAC1 and VPAC2 class B G protein-coupled receptors through receptor recognition involving their extracellular domains. These receptors preferentially couple to Gαs, which activates adenylyl cyclase and increases intracellular cAMP.
The resulting cAMP signal can activate protein kinase A (PKA) and EPAC. Experimental studies also report coupling through Gαq or Gαi, with activation of phospholipase C, calcium signaling and protein kinase C under specific conditions. The relative contribution of these pathways varies between receptor subtypes and cellular systems, and their full signaling relationships remain under investigation.
Scientific Research Context
VIP has been studied across a large body of laboratory literature, with work spanning biochemical studies, cell experiments, tissue preparations, and animal research. The literature has expanded over time from basic characterization of the peptide to more detailed investigation of its biological properties. In vitro experiments and preclinical animal models make up a major part of the evidence base, while human studies form a smaller portion. Overall, the literature is broad, although the strength of evidence differs between research areas.
VIP Biology and Biological Pathways
Primary Biological Function
VIP is an endogenous neuropeptide found in the central and peripheral nervous systems. Published literature describes its role as a neurotransmitter and neuromodulator, with functions involving regulation of smooth-muscle activity, secretion, vascular tone, and neuroendocrine signaling. Its distribution in neuronal tissues supports its role as a signaling molecule in both neural and peripheral systems.
Relevant Metabolic or Signalling Pathways
VIP-related biology has been examined across several intracellular signaling pathways. Published work identifies cyclic AMP as a major second messenger associated with VPAC receptor activity. Other studies have examined calcium signaling, phospholipase pathways, protein kinases and transcriptional responses. Researchers investigate these pathways to define how VIP receptor activity is translated into cellular responses.
Tissue-Specific Biology
VIP-containing neurons occur in the brain and peripheral nervous system, including the gastrointestinal and genitourinary tracts. Receptor expression also varies between tissues. VPAC1 has been detected widely in epithelial and glandular tissues while VPAC2 is more prominent in vascular and smooth-muscle tissues. These distribution patterns are investigated to characterize tissue-specific VIP signaling.
Experimental Biomarkers
VIP studies have used measurements such as VIP concentration, VPAC1 and VPAC2 expression, intracellular cAMP, intracellular calcium, receptor abundance, and downstream protein phosphorylation. In tissue and animal experiments, investigators have also measured cytokines, myeloperoxidase, and other molecular markers when examining VIP-associated biological responses. The selected marker depends on the biological system under investigation.
Laboratory Investigation Methods
Published VIP studies have used immunohistochemistry, immunofluorescence, receptor autoradiography, ligand-binding assays and cell-based measurements to examine peptide and receptor distribution. Studies have also used Western blotting to identify signaling components and biochemical assays to measure intracellular cAMP or calcium. These methods have been applied to cells, tissue sections, and isolated tissue preparations.
Experimental Models Used in Published Research
Published VIP research includes cell-based systems, ex vivo intestinal tissue, intestinal organoids, conventional mice, and genetically modified mice. These models differ in how closely they reproduce intact physiology, making their limitations important when interpreting experimental findings.
Cell-Based Models
Published VIP studies have used HT-29 and other human colonic adenocarcinoma cell lines, as well as CHO and HEK293 cells expressing recombinant VIP receptors. Their main limitation is that cultured or transfected cells do not reproduce intact tissue architecture or the full cellular environment.
Ex Vivo Intestinal Tissue
Organotypic intestinal slices retain multiple cell types and elements of the intestinal wall outside the animal. Their limitation is the loss of normal systemic influences and the gradual alteration of tissue conditions during ex vivo culture.
Intestinal Organoids
Intestinal organoids derived from mouse or human intestinal tissue have been used as three-dimensional epithelial models in VIP research. Their limitation is that they contain mainly epithelial components and lack the full vascular, neural, immune and systemic environment of an intact intestine.
Conventional Mouse Models
Mice are used as intact mammalian models in VIP research. Their main limitation is the difference between mouse and human biology, including species-specific receptor expression, tissue organization and physiological regulation.
VIP-Deficient Mice
VIP-deficient mice carry a targeted deletion of the Vip gene and lack endogenous VIP. A key limitation is that this is a lifelong genetic model. so developmental changes may influence the phenotype and complicate separation of effects caused specifically by loss of VIP.
VPAC1- and VPAC2-Deficient Mice
VPAC1- and VPAC2-deficient mice are genetic models in which the corresponding receptor genes are disrupted. Their main limitation is that receptor deletion can produce genotype-related changes, including altered development or physiology which can complicate interpretation of findings attributed specifically to the missing receptor.
Published Research
VIP Receptor Biology
Published studies have examined VPAC1 and VPAC2 receptor distribution, expression, molecular structure, ligand binding, receptor subtype differences, tissue localization and receptor variants.
Gastrointestinal Biology
The literature has examined VIP in relation to intestinal motility, secretion, epithelial regulation, and gastrointestinal tissue organization. Studies have also investigated the distribution of VPAC1 along the intestine and its localization within intestinal epithelial tissue. More recent work has examined VIP-associated regulation of intestinal epithelial and stem-cell biology.
Immune Biology
VIP-related immune research has examined immune-cell activity, cytokine regulation, receptor expression, and communication between neural and immune systems. Published work has considered VIP production by immune cells as well as VIP receptor expression on different immune-cell populations.
Neural and Neuroendocrine Biology
Studies have examined the distribution of VIP within the central and peripheral nervous systems and the tissue distribution of its receptors. Research has also characterized receptor expression in brain regions associated with neural and neuroendocrine functions, including the hypothalamus and pituitary.
Vascular and Smooth-Muscle Biology
Research has examined VIP receptor expression in blood vessels and smooth-muscle tissues. Studies have characterized VPAC2 distribution in vascular and gastrointestinal smooth muscle and investigated the presence of VIP/PACAP receptors in human vascular tissues.
Respiratory Biology
VIP research has also examined VIP-containing nerve fibers and receptor distribution in the respiratory tract. Studies have characterized VPAC1 and VPAC2 localization within human lung tissue, including their distribution among different pulmonary structures.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The VIP literature contains extensive experimental and physiological research, but much of the evidence concerning specific biological effects comes from cellular, tissue, and animal studies. These findings establish biological observations but do not by themselves establish how consistently the same effects occur in humans.
Human Clinical Evidence
Human research on VIP exists, but clinical application has remained limited. Published reviews identify rapid enzymatic degradation, short plasma half-life, and difficulties with delivery as important constraints. These factors have limited the development and interpretation of studies involving systemic VIP exposure.
Species Differences
Differences in VIP sequence and receptor structure between species can limit direct comparison of experimental findings. Published studies have identified species dependent differences in receptor binding properties and receptor sequence, including differences between rat and human VPAC receptors.
Study Design Limitations
VIP studies use diverse experimental conditions, receptor systems, tissues, and biological endpoints. This heterogeneity makes direct comparison between individual studies difficult. Differences in peptide exposure, receptor expression, experimental preparation, and measurement methods can also influence the findings reported across studies.
Independent Replication
The VIP literature is broad, but replication is not uniform across all research areas. Some findings have been examined across different experimental systems, whereas other observations rely on narrower groups of studies. This uneven distribution of evidence limits the strength of conclusions for some specific biological questions.
Long-Term Evidence
Limited long-term evidence is a limitation of VIP research. Published work has documented chronic experimental exposure, but the literature remains less developed for prolonged systemic exposure and sustained biological effects of native VIP. Rapid degradation also limits studies requiring persistent exposure.
Analytical Documentation
HPLC is used in research to separate and characterize peptide material. Published studies have applied reversed-phase, ion-exchange and gel-permeation chromatography to characterize VIP and assess peptide purity and identity.
LC-MS provides molecular-mass information and can help identify VIP and related peptide products or degradation fragments. Published VIP studies have used mass spectrometric analysis alongside chromatographic separation to characterize peptides.
NMR can provide structural information about peptide conformation. NMR studies have been used to examine VIP fragments and VIP analogues at the molecular level.
A Certificate of Analysis (CoA) records analytical test results associated with a specific product batch. Such documentation helps establish identity, purity, and measured quality characteristics. Analytical documentation verifies product identity and quality rather than biological performance.
Storage and Laboratory Handling
Store VIP at 2–8°C and follow the storage conditions specified for the product. Laboratory handling should be carried out by qualified personnel using clean procedures that reduce the risk of contamination.
Keep the material protected from unnecessary environmental exposure during handling and storage. The container should remain properly closed when not in use.
Storage and handling conditions may affect peptide integrity, so the specified temperature should be maintained. VIP is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.